|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The pleotropic cytokine tumor necrosis factor (TNF) is involved in the pathophysiology of multiple sclerosis (MS).
|
31785393 |
2020 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
In PP, tumor necrosis factor-α correlated with MS Severity Score.
|
31726376 |
2020 |
|
Multiple Sclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Therefore, plasma LEP levels and mRNA expression of five genes related to the LEP signaling pathway (LEP, LEP receptor (LEPR), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1A), superoxide dismutase 2, tumor necrosis factor-alpha) were investigated in relapsing-remitting MS.
|
31704454 |
2020 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The course of MS is associated with the secretion of many inflammatory and oxidative stress mediators, including cytokines (IL-1b, IL-6, IL-17, TNF-α, INF-γ) and chemokines (MIP-1a, MCP-1, IP10).
|
31284389 |
2019 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Remarkably, an adaptive NK cell phenotype did not directly correlate with enhanced antibody-triggered degranulation and TNFα production in MS in contrast to controls.
|
31681293 |
2019 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
In the present study, serum level of eight cytokines (IL-1β, IL-2, IL-4, IL-8, IL-10, IL-13, IFN-γ, and TNF-α) was analyzed in USA and Russian MS to identify predictors for the disease.
|
31379730 |
2019 |
|
Multiple Sclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Both CMS and MS-SCON patients displayed reduced IL-8 and CXCL2 and increased TNF-α levels, while IL-10 and CXCL5 levels were identical among all groups.
|
31556809 |
2019 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results of WGCNA and GSEA showed that a potential important function of lncRNAs in MS may be involved in the regulation of ribonucleoproteins and tumor necrosis factor cytokines receptors.
|
31781177 |
2019 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
To examine whether TNF-α, sTNFR1 and sTNFR2 are associated with MS diagnosis, disability, disability progression and clinical forms of MS.
|
31559449 |
2019 |
|
Multiple Sclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this study, the effects of curcumin has been investigated on the expression levels of selected cytokine coding genes as well as the extent of demyelination in the corpus callosum of C57BL/6 experimental autoimmune encephalomyelitis (EAE) model of MS. Gene expression analyses revealed that treatment with curcumin could lead to a significant reduction in the expression levels of pro-inflammatory cytokine coding genes including IL-6 (p = 0.001), IL-17 (p = 0.001), tumor necrosis factor (TNF)-α (p = 0.008), and interferon (IFN)-γ (p = 0.033) as well as a significant increase in the expression level of transforming growth factor (TGF)-β (p = 0.006) as an anti-inflammatory cytokine.
|
31033006 |
2019 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The protective and anti-inflammatory effects of TNFR2 may explain why TNF inhibitors failed to be effective in diseases such as heart failure or multiple sclerosis, where TNF has been strongly implicated as a driving force.
|
30856027 |
2019 |
|
Multiple Sclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A rare variant (BAFF-var) of the tumor necrosis factor superfamily 13b (TNFSF13B) gene has been recently associated with multiple sclerosis (MS) and systemic lupus erythematosus (SLE).
|
29844438 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-<i>β</i> and TNF are increased in the brain of MS patients and contribute to induce the changes in synaptic plasticity occurring in MS patients and its animal model, the experimental autoimmune encephalomyelitis (EAE).
|
29861718 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-alpha (TNFα) was not associated with MS risk in persons with inflammatory bowel disease (standard morbidity ratio = 4.2;95%CI:0.1-23.0) and arthritis (standardized incidence ratio = 1.38;95%CI:0.69-2.77); however, men exposed to anti-TNFα who also had arthritis and individuals with ankylosing spondylitis were at an increased risk (standardized incidence ratios = 3.91;95%CI:1.47-10.42 and 3.48;95%CI:1.45-8.37, respectively).
|
29210147 |
2018 |
|
Multiple Sclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Besides, vitamin D intake, through the proliferation decrement of pro-inflammatory cells, decreases of pro-inflammatory markers (IL-6, TNF-α, INF-γ) and auto-immune pathways have potential role in recovery of irregular menstruation in women with the low level of testosterone as a red warning factor of MS development.
|
27966076 |
2018 |
|
Multiple Sclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1 β), and tumor necrosis factor-α (TNF-α) are associated with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
|
28856541 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Tumour necrosis factor (TNF) signalling is mediated via two receptors, TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2), which work antithetically to balance CNS immune responses involved in autoimmune diseases such as multiple sclerosis.
|
30206422 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The aims of this study were to verify whether hyperhomocysteinemia is associated with disability progression in Multiple Sclerosis (MS) patients and whether TNF pathways and cellular adhesion molecules (CAM) are involved in this process.
|
29797117 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
We found that compared with placebo, probiotic supplementation down-regulated gene expression of interleukin-8 (IL-8; p < 0.001) and tumor necrosis factor-alpha (TNF-α) mRNA (p < .001) in peripheral blood mononuclear cells of patients with MS. We did not observe any significant effect of probiotic supplementation on gene expression of interleukin-1 (IL-1), peroxisome proliferator-activated receptor gamma (PPAR-γ), or oxidized low-density lipoprotein receptor (LDLR) in peripheral blood mononuclear cells of patients with MS.
|
28922099 |
2018 |
|
Multiple Sclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The observation of TNF-α expression by CD4+ and CD8+ T cells expressing EZH2 warrants additional studies to explore more in depth the pathogenic potential of EZH2+-positive cells in MS.
|
30367633 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Second, we assess the astrocytic response to IL-1β, TNF-α, and IL-6, all cytokines important in neuroinflammation, such as multiple sclerosis.
|
30409508 |
2018 |
|
Multiple Sclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have highlighted the role of tumour necrosis factor receptor superfamily member 1A (TNFRSF1A) gene encoding the type 1 TNF receptor in the genetic predisposition to MS.
|
30009568 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, clinical studies with a non-selective inhibitor of TNFα in MS patients had to be halted due to exacerbation of clinical symptoms.
|
29760711 |
2018 |
|
Multiple Sclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although TNF-targeted therapies have been largely unsuccessful in MS, recent preclinical data suggests selective soluble TNF inhibition can promote remyelination.
|
29690885 |
2018 |
|
Multiple Sclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
MP treatment induced significant amplification in the transcript levels of iNOS and TNF-α (M1-related markers) in the corpus callosum of the MS mice, whereas no change detected in the expression of IL-10 (M2-related marker) between the groups.
|
30143908 |
2018 |